Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
Rhea-AI Summary
Sanuwave (NASDAQ: SNWV) will host a live conference call to present its Q3 2025 financial results on Friday, November 7, 2025 at 8:30 AM ET. Telephone access: Toll-Free 1-800-274-8461 or International 1-203-518-9814 with Conference ID SANUWAVE. Instant telephone access is available via the webcast link. Materials will be posted at www.sanuwave.com/investors. A replay will be available through November 28, 2025 via Toll-Free 1-844-512-2921 or 1-412-317-6671 using Replay Access ID 11160405.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SNWV gained 0.29%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results.
Telephone access to the call will be available by dialing the following numbers:
Participant Dial-in Information
Toll Free: 1-800-274-8461
Toll/International: 1-203-518-9814
Conference ID: SANUWAVE
OR click the link for instant telephone access to the event:
https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3b515a
Materials for the conference call will be included on the Company’s website at
www.sanuwave.com/investors.
A replay will be made available through November 28, 2025:
Toll-Free: 1-844-512-2921 or 1-412-317-6671
Replay Access ID: 11160405
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact:
FAQ
When will Sanuwave (SNWV) present Q3 2025 results and what time is the call?
How can investors join the Sanuwave (SNWV) Q3 2025 conference call by phone?
Where can I find the Sanuwave (SNWV) Q3 2025 presentation materials and webcast link?
Will there be a replay of the Sanuwave (SNWV) Q3 2025 earnings call and how long is it available?
What is the conference ID for Sanuwave's (SNWV) November 7, 2025 earnings call?
